RCHA - Third Party independent coverage of RCHA as of this morning.
We most likely will go much higher if there are groups covering RCHA.
This is only the start.
Company Research Highlights
®
Report created on May 19, 2016
This is not an investment recommendation from Fidelity Investments. Fidelity provides this information as a service to investors from independent, third-party sources.
Performance of analyst recommendations are provided by Thomson Reuters Starmine. Current analyst recommendations are collected and standardized by Investars.
See each section in this report for third-party content attribution, as well as the final page of the report for additional important information regarding third-party content.
Page 1
Important Information Regarding Third-Party Content
RICH PHARMACEUTICA COM USD0.001 POST
REV SPLIT
Other OTC:RCHA
9595 Wilshire Boulevard, Suite 900
Beverly Hills, CA 90212
USA
424-230-7001
www.richpharmaceuticals.com
Price on 5/18/2016:
$0.0005
Market Capitalization:
$352.72
Business Description
Data provided by S&P Compustat
Rich Pharmaceuticals, Inc., a development stage company, engages in developing PD-616 for
the treatment of acute myelogenous leukemia and hodgkin's lymphoma. The company was
formerly known as Nepia Inc. and changed its name to Rich Pharmaceuticals, Inc., in August
2013.
Key Statistics
Employee Count
--
AI
